drugset / Trial / NCT03454620
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to assess the safety and tolerability of GC1118 in combination with irinotecan or FOLFIRI in order to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D)
Timeline
- Start
- 2018-04-02
- Primary completion
- 2021-09-17
- Completion
- 2022-01-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |